melagatran has been researched along with Blood Clot in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (93.33) | 29.6817 |
| 2010's | 2 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adang, AE; de Man, AP; Grootenhuis, PD; Kelder, J; Lucas, H; Meuleman, DG; Peters, CA; Rewinkel, JB; Smit, MJ; van Aelst, S; van Boeckel, CA; van Dinther, T; Visser, A; Vogel, GM | 1 |
| Cho, KH; Kim, A; Kim, TH; Lee, SH; Park, HD | 1 |
| Bergmann, JF; Lloret Linares, C | 1 |
| Lassila, R | 1 |
| Fenyvesi, T; Harenberg, J; Jörg, I; Piazolo, L; Zokai, K | 1 |
| Carlsson, S; Elg, M; Mattsson, C | 1 |
| Haas, S | 1 |
| Björnheden, T; Carlsson, S; Grip, L; Mattsson, C; Scherstén, F; Wahlund, G | 1 |
| Elg, M; Gustafsson, D | 1 |
| Eriksson, BI | 1 |
| Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI | 1 |
| Gustafsson, D | 1 |
| Elalamy, I; Lebrazi, J; Samama, MM | 1 |
| Boström, SL; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Levi, M; Sarich, TC; Svensson, M; Wåhlander, K; Weitz, JI; Wolzt, M | 1 |
| Weitz, J | 1 |
| Bauersachs, RM | 1 |
| Samama, MM | 1 |
| Furugohri, T; Honda, Y; Isobe, K; Matsumoto, C; Muramatsu, S; Shiozaki, Y; Sugiyama, N | 1 |
| Meyer Samama, M | 1 |
| Attman, PO | 1 |
| Carlsson, S; Gruber, A; Hanson, SR; Kotzé, HF; Marzec, U; Sarich, TC | 1 |
| Badimon, JJ; Bylock, A; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Kalies, I; Nyström, P; Sarich, TC; Wåhlander, K | 1 |
| Agnelli, G; Andersson, M; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Mouret, P; Ogren, M; Panfilov, S; Rosencher, N | 1 |
| Carlsson, S; Elg, M; Gustafsson, D | 1 |
| Heinzl, S | 1 |
| Fleischer, K; Gulba, DC; Lankes, W | 1 |
| Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H | 1 |
| Ekdahl, KN; Elgue, G; Korsgren, O; Larsson, R; Nilsson, B; Ozmen, L | 1 |
9 review(s) available for melagatran and Blood Clot
| Article | Year |
|---|---|
[Thrombosis in spite of warfarin--what should be done?].
Topics: Anticoagulants; Antiphospholipid Syndrome; Azetidines; Benzylamines; Blood Coagulation; Glycine; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Neoplasms; Recurrence; Thrombin; Thrombosis; Treatment Failure; Warfarin | 2001 |
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
Topics: Azetidines; Benzylamines; Glycine; Hemostasis; Humans; Pharmacokinetics; Prodrugs; Thrombin; Thrombosis | 2003 |
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboembolism; Thrombosis; Treatment Outcome | 2003 |
Oral direct thrombin inhibitors in clinical development.
Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; Prodrugs; Pyridines; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
Orally active direct thrombin inhibitors.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Blood Coagulation; Drug Monitoring; Glycine; Humans; International Normalized Ratio; Postoperative Complications; Prodrugs; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
[Low molecular weight heparin, fondaparinux and melagatran: new data and clinical studies].
Topics: Angina, Unstable; Animals; Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Thrombosis | 2004 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Hirudins; Humans; Injections, Subcutaneous; Platelet Aggregation Inhibitors; Polysaccharides; Prodrugs; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Venous Thrombosis | 2005 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2001 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis | 2001 |
4 trial(s) available for melagatran and Blood Clot
| Article | Year |
|---|---|
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboembolism; Thrombosis; Treatment Outcome | 2003 |
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Topics: Adult; Azetidines; Benzylamines; Biomarkers; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Interactions; Factor VII; Factor VIIa; Glycine; Humans; Male; Platelet Activation; Recombinant Proteins; Single-Blind Method; Thrombosis; Time Factors | 2004 |
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Topics: Administration, Oral; Adult; Anticoagulants; Arteries; Aspirin; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation; Clopidogrel; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombin; Thrombosis; Ticlopidine | 2006 |
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty; Aspirin; Azetidines; Benzylamines; Bleeding Time; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Enoxaparin; Europe; Female; Humans; Lower Extremity; Male; Middle Aged; Platelet Aggregation Inhibitors; South Africa; Thrombosis | 2006 |
18 other study(ies) available for melagatran and Blood Clot
| Article | Year |
|---|---|
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.
Topics: Administration, Oral; Animals; Aorta; Biological Availability; Biological Transport, Active; Caco-2 Cells; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrinolytic Agents; Half-Life; Humans; In Vitro Techniques; Models, Molecular; Oligopeptides; Rats; Structure-Activity Relationship; Thrombin; Thrombosis | 2002 |
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.
Topics: Amidines; Animals; Antithrombins; Dipeptides; Dogs; Fluoroacetates; Haplorhini; Humans; Prodrugs; Rabbits; Rats; Thrombin; Thrombosis | 2013 |
[Story of a predictable death: the end of vitamin K antagonists?].
Topics: Anticoagulants; Azetidines; Benzylamines; France; Hemorrhage; Humans; Pulmonary Embolism; Thromboembolism; Thrombosis; Venous Thrombosis; Vitamin K | 2010 |
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
Topics: Antithrombin III; Azetidines; Benzylamines; Fibrin; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Hirudins; Humans; Models, Cardiovascular; Peptide Hydrolases; Platelet Activation; Platelet Factor 4; Thrombin; Thrombosis | 2002 |
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hirudins; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Thrombosis; Venae Cavae | 2002 |
Melagatran. Exanta, H 319/68.
Topics: Animals; Azetidines; Benzylamines; Dogs; Fibrinolytic Agents; Glycine; Humans; Mice; Thrombosis | 2002 |
[New anticoagulants -- their clinical significance].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Biological Availability; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Glycine; Humans; Meta-Analysis as Topic; Polysaccharides; Prodrugs; Risk Factors; Stroke; Thrombosis | 2003 |
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Glycine; Humans; Phenprocoumon; Placebos; Prodrugs; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2003 |
Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
Topics: Angioplasty, Balloon, Coronary; Animals; Azetidines; Benzylamines; Blood Platelets; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fibrin; Fibrinolytic Agents; Glycine; Male; Models, Animal; Platelet Adhesiveness; Radioactive Tracers; Swine; Thrombosis | 2003 |
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Glycine; Hemorrhage; Hirudin Therapy; Hirudins; Male; Rabbits; Risk Assessment; Thrombin; Thrombosis | 2003 |
In vitro effect of melagatran and lepirudin on clot-bound thrombin.
Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinant Proteins; Thrombin; Thrombosis | 2003 |
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs].
Topics: Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Thrombin; Thrombosis | 2004 |
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Glycine; Male; Naphthalenes; Propionates; Rats; Rats, Wistar; Thrombin; Thromboplastin; Thrombosis | 2005 |
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Topics: Anticoagulants; Azetidines; Benzylamines; Chronic Disease; Humans; Renal Dialysis; Thrombin; Thrombosis; Uremia | 2006 |
Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Case-Control Studies; Factor VIIa; Hemostasis; Humans; Male; Papio; Protein C; Recombinant Proteins; Thrombosis; Time Factors | 2007 |
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation; Blood Coagulation Factors; Drug Interactions; Factor VII; Factor VIIa; Glycine; Male; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Thrombosis | 2001 |
[New thrombolytic agents].
Topics: Anticoagulants; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin; Humans; Thrombosis; Venous Thrombosis | 2001 |
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation.
Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Blood Platelets; Cadaver; CD11 Antigens; Female; Fibrin; Glycine; Humans; Immunohistochemistry; Inflammation; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Middle Aged; Neutrophils; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thrombosis | 2002 |